Management of Superficial Thrombophlebitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis

In brief

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

Key facts

Study ID

NCT00264381

Run by

University of Oklahoma

People needed

72

Starts

2002-10-01

Expected to finish

2011-09-01

Last updated by the study team

2013-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging

You may not qualify if…

• Active, clinically significant bleeding
• Known hypersensitivity to NSAIDS, heparin or derivatives
• Currently pregnant or < 1 week post-partum
• Acquired bleeding diathesis
• Known inherited bleeding disorder
• Renal failure
• Extremes of weight
• unable to return for repeat diagnostic testing or follow-up visit
• Concurrent deep-vein thrombosis

Where it is running

• Department of Veterans Affairs Medical Center — Oklahoma City, Oklahoma, United States
• University of Oklahoma Health Science Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.